Get the Stockscreener App
9.075
3.98%
-0.475
Champions Oncology Inc Stock (CSBR) Forecast
The Champions Oncology Inc (CSBR) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $2.066, representing a -77.23% decrease from the current price of $9.075. The highest analyst price target is $3.5632, and the lowest is $0.5688.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CSBR Price Target
Average 5.3935
(-40.57% Downside)
Is Champions Oncology Inc (CSBR) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 41.77 | Neutral |
| STOCH(9,6) | 31.81 | Neutral |
| STOCHRSI(14) | 35.74 | Neutral |
| MACD(12,26) | -0.1897 | Sell |
| ADX(14) | 17.68 | Neutral |
| William %R | -75.03 | Neutral |
| CCI(14) | -103.80 | Sell |
Buy: 0
Sell: 2
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
9.8805
Sell
|
9.7472
Sell
|
| MA20 |
10.13
Sell
|
9.9848
Sell
|
| MA50 |
10.21
Sell
|
9.5629
Sell
|
| MA100 |
7.6034
Buy
|
8.3377
Buy
|
| MA200 |
6.1553
Buy
|
7.1046
Buy
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, CSBR could be considered a Moderate Sell, with 17 technical analysis indicators signaling 4 Buy signals, 8 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on CSBR, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 41.77 indicates that CSBR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 31.81 indicates that CSBR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 35.74 indicates that CSBR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.68 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -103.8 indicates that CSBR is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term CSBR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Champions Oncology Inc financial reports and earnings history, Champions Oncology Inc (CSBR) stock could reach $3.0439 by 2030, $2.8012 by 2040 and $5.999 by 2050. See the projected annual prices until 2050 of the Champions Oncology Inc stock below:
- Champions Oncology Inc (CSBR) is expected to reach an average price of $0.9785 in 2035, with a high prediction of $1.2846 and a low estimate of $0.5856. This indicates an $-89.22% rise from the last recorded price of $9.075.
- Champions Oncology Inc (CSBR) stock is projected to chart a bullish course in 2040, with an average price target of $2.4218, representing an $-73.31% surge from its current level. The forecast ranges from a conservative $2.4218 to a sky-high $2.8012.
- Our analysts predict Champions Oncology Inc (CSBR) to jump -66.80% by 2045, soaring from $2.8171 to an average price of $3.0132, potentially reaching $2.6332. While $2.8171 is the low estimate, the potential upside is significant.
- Champions Oncology Inc (CSBR) stock is expected to climb by 2050, reaching an average of $5.5667, a $-38.66% jump from its current level. However, a wide range of estimates exists, with high and low targets of $5.999 and $6.279, respectively, highlighting the market's uncertainty.
Champions Oncology Inc Stock (CSBR) Year by Year Forecast
Champions Oncology Inc Stock (CSBR) Price Forecast for 2025
Champions Oncology Inc Stock (CSBR) is expected to reach an average price of $4.0614 in 2025, with a high prediction of $7.554 and a low estimate of $0.5688. This indicates an -55.25% fall from the last recorded price of $9.075.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| April, 2025 | $3.5398 | $0.5688 | $3.5632 | -60.99% |
| May, 2025 | $3.7217 | $3.1253 | $4.1062 | -58.99% |
| June, 2025 | $5.6737 | $4.0772 | $6.3237 | -37.48% |
| July, 2025 | $5.7811 | $4.8592 | $6.5946 | -36.30% |
| August, 2025 | $6.423 | $5.3766 | $6.913 | -29.22% |
| September, 2025 | $5.545 | $4.7295 | $7.554 | -38.90% |
| October, 2025 | $4.7224 | $4.5524 | $6.6505 | -47.96% |
| November, 2025 | $5.9744 | $3.7579 | $6.2789 | -34.17% |
| December, 2025 | $5.5318 | $4.8253 | $6.3553 | -39.04% |
Champions Oncology Inc Stock (CSBR) Price Forecast for 2026
The predicted value for Champions Oncology Inc (CSBR) in 2026 is set at an average of $8.3021. Estimates vary from a peak of $11.55 to a trough of $5.0573, indicating an -8.52% surge from the present price of $9.075.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $8.1437 | $5.0573 | $10.22 | -10.26% |
| February, 2026 | $8.0557 | $7.1957 | $8.7802 | -11.23% |
| March, 2026 | $8.0576 | $6.8622 | $8.2967 | -11.21% |
| April, 2026 | $8.1951 | $7.2551 | $9.4386 | -9.70% |
| May, 2026 | $9.337 | $7.6615 | $11.55 | +2.89% |
| June, 2026 | $8.2089 | $6.9489 | $10.02 | -9.54% |
| July, 2026 | $6.4664 | $5.7209 | $8.7594 | -28.75% |
| August, 2026 | $6.5183 | $5.9883 | $7.2673 | -28.17% |
| September, 2026 | $6.6157 | $5.3938 | $8.2048 | -27.10% |
| October, 2026 | $7.5877 | $6.0412 | $7.8548 | -16.39% |
| November, 2026 | $6.6996 | $6.2396 | $7.8332 | -26.17% |
| December, 2026 | $7.2471 | $6.6006 | $8.0151 | -20.14% |
Champions Oncology Inc Stock (CSBR) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Champions Oncology Inc (CSBR) is $5.7528, with a high forecast of $7.45 and a low forecast of $4.0555. This indicates an -36.61% decrease from the last price of $9.075.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $7.029 | $6.918 | $7.3725 | -22.55% |
| February, 2027 | $6.4509 | $6.2709 | $7.45 | -28.92% |
| March, 2027 | $5.1984 | $4.9029 | $6.3764 | -42.72% |
| April, 2027 | $5.1603 | $4.864 | $6.2532 | -43.14% |
| May, 2027 | $4.9711 | $4.7413 | $5.3158 | -45.22% |
| June, 2027 | $5.3197 | $4.2578 | $5.7797 | -41.38% |
| July, 2027 | $5.3316 | $4.2507 | $6.1207 | -41.25% |
| August, 2027 | $5.1339 | $4.6637 | $5.8626 | -43.43% |
| September, 2027 | $4.521 | $4.0555 | $5.1691 | -50.18% |
| October, 2027 | $4.843 | $4.483 | $5.173 | -46.63% |
| November, 2027 | $5.1949 | $4.6502 | $5.5299 | -42.76% |
| December, 2027 | $6.7923 | $4.8025 | $7.2023 | -25.15% |
Champions Oncology Inc Stock (CSBR) Price Forecast for 2028
In 2028, Champions Oncology Inc (CSBR) is projected to reach an average price of $4.0354, with a high projection of $6.8778 and a low estimate of $1.193. This indicates an -55.53% fall from the last price of $9.075.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $4.9643 | $4.8443 | $6.8778 | -45.30% |
| February, 2028 | $4.8662 | $4.5098 | $6.5107 | -46.38% |
| March, 2028 | $4.3336 | $4.2882 | $5.2726 | -52.25% |
| April, 2028 | $4.2106 | $3.5147 | $4.6544 | -53.60% |
| May, 2028 | $1.923 | $1.193 | $4.6366 | -78.81% |
| June, 2028 | $1.545 | $1.545 | $2.1385 | -82.98% |
| July, 2028 | $1.6169 | $1.5204 | $1.8214 | -82.18% |
| August, 2028 | $2.0042 | $1.5924 | $2.2934 | -77.91% |
| September, 2028 | $2.0563 | $1.4753 | $2.1263 | -77.34% |
| October, 2028 | $2.7282 | $1.9082 | $3.0873 | -69.94% |
| November, 2028 | $2.8257 | $1.7337 | $2.9646 | -68.86% |
| December, 2028 | $3.9876 | $2.6911 | $4.4066 | -56.06% |
Champions Oncology Inc Stock (CSBR) Price Forecast for 2029
The 2029 price forecast for Champions Oncology Inc Stock (CSBR) is $2.9103 on average, with a high prediction of $4.9441 and a low estimate of $0.8766. This represents an -67.93% decrease from the previous price of $9.075.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $4.135 | $3.7231 | $4.9441 | -54.43% |
| February, 2029 | $4.257 | $3.746 | $4.576 | -53.09% |
| March, 2029 | $2.9289 | $2.8389 | $4.4479 | -67.73% |
| April, 2029 | $3.8509 | $2.7844 | $4.3304 | -57.57% |
| May, 2029 | $3.3083 | $2.8628 | $4.7256 | -63.55% |
| June, 2029 | $3.0502 | $2.7602 | $3.4838 | -66.39% |
| July, 2029 | $3.3921 | $2.2768 | $3.6372 | -62.62% |
| August, 2029 | $3.6096 | $3.1777 | $4.9189 | -60.22% |
| September, 2029 | $3.5015 | $3.4561 | $4.0706 | -61.42% |
| October, 2029 | $3.249 | $2.7346 | $4.088 | -64.20% |
| November, 2029 | $2.9309 | $2.6304 | $3.1654 | -67.70% |
| December, 2029 | $1.14 | $0.8766 | $3.0149 | -87.44% |
Champions Oncology Inc Stock (CSBR) Price Forecast for 2030
Champions Oncology Inc Stock (CSBR) is expected to reach an average price of $1.56 in 2030, with a high forecast of $3.0439 and a low forecast of $0.0762. This signifies an -82.81% decrease from the last price of $9.075.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.2933 | $0.591 | $3.0439 | -85.75% |
| February, 2030 | $0.7587 | $0.1578 | $1.5758 | -91.64% |
| March, 2030 | $1.2874 | $0.1697 | $1.8707 | -85.81% |
| April, 2030 | $1.8635 | $1.6644 | $1.1964 | -79.47% |
| May, 2030 | $1.5786 | $1.2415 | $1.5786 | -82.60% |
| June, 2030 | $1.4547 | $1.5247 | $1.3276 | -83.97% |
| July, 2030 | $1.6299 | $1.8928 | $1.6618 | -82.04% |
| August, 2030 | $0.344 | $0.196 | $1.734 | -96.21% |
| September, 2030 | $1.0179 | $0.436 | $1.6479 | -88.78% |
| October, 2030 | $0.1628 | $0.1472 | $1.6739 | -98.21% |
| November, 2030 | $1.2133 | $0.0762 | $0.4737 | -86.63% |
| December, 2030 | $0.2395 | $0.3095 | $0.9024 | -97.36% |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):